A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors



Status:Recruiting
Conditions:Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/6/2018
Start Date:August 31, 2017
End Date:December 5, 2020
Contact:Recruiting sites have contact information. Please contact the sites directly. If there is no contact information
Email:Clinical.Trials@bms.com
Phone:please email:

Use our guide to learn which trials are right for you!

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

The purpose of this study is to investigate BMS-986226 administered alone or in combination
with nivolumab or ipilimumab.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Advanced solid tumors

- Histological or cytological confirmation of a malignancy that is advanced (metastatic
and/or unresectable) with measureable disease as defined by Response Evaluation
Criteria In Solid Tumors (RECIST) v1.1

- At least 1 lesion accessible for biopsy in addition to the target lesion

- Participants must have received, and then progressed or been intolerant to, at least 1
standard treatment regimen

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

Exclusion Criteria:

- Participants with active central nervous system (CNS) metastases, untreated CNS
metastases, or with the CNS as the only site of disease are excluded (controlled brain
metastases will be allowed to enroll)

- Participants with carcinomatous meningitis

- Prior malignancy active within the previous 2 years except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast

- Active, known, or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
5
sites
Philadelphia, Pennsylvania 19111
Phone: 215-728-5682
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Boston, Massachusetts 02111
?
mi
from
Boston, MA
Click here to add this to my saved trials
92 2nd St
Hackensack, New Jersey 07601
(201) 996-5900
John Theurer Cancer Center at the Hackensack University Medical Center The mission of the John...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hamilton, Ontario
?
mi
from
Hamilton,
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials